Three verys: ABBV/ENTA’s HCV regimen has the potential to be “a very, very, very big” product, said Bill Chase (CFO) at ABBV’s CS webcast today. My own projection of peak sales is $3B (#msg-92234861), so I guess that qualifies, LOL.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”